Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
NANO MRNA Co.,Ltd. (4571.T)
JPY106.00
+2.00 (+1.92%)
JP JPX Healthcare Biotechnology
Address
Onoya-Kyobashi Building 104-0031
Tokyo, JP
Tokyo, JP
CEO
Shiro Akinaga
Website
nanomrna.co.jp
IPO
2008-03-05
ISIN JP3651120002
Description
NANO MRNA Co., Ltd. specializes in the discovery, advancement, and manufacturing of pharmaceutical products, employing its innovative micellar nanoparticle platform. Its biopharmaceutical pipeline is primarily geared towards addressing oncological conditions and a range of other severe illnesses. The enterprise also undertakes the full spectrum of activities for anti-cancer medications, from initial scientific investigation to market commercialization, all underpinned by its distinctive micellar nanoparticle approach. Established on June 14, 1996, by Kazunori Kataoka, Teruo Okano, and Ichiro Nakatomi, the firm maintains its principal operations in Tokyo, Japan.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
JPY106.00
+2.00 (+1.92%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
638.6K
Beta
0.36
Float Shares
65.62M
Free Float %
88.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.49% | -3.55% | -9.33% | -16.56% | -9.33% | -4.23% | +5.43% | -40.61% | -50.90% | -90.59% | -50.55% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
106.00
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
1.96
Grey zone
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+60.8% ★ Q1'26: +71.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-8.9% Q1'26: -13.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-86.6% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-553.6% Q1'26: -833.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-378.2% Q1'26: -568.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+3.7% Q1'26: +9.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.66× Q1'26: -1.10× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
675.80M
est: 670.00M (+0.9%)
|
243.34M
est: 204.00M (+19.3%)
|
218.69M
est: 345.00M (-36.6%)
|
259.10M
est: 216.67M (+19.6%)
|
496.73M
est: 473.00M (+5.0%)
|
552.97M
est: 550.00M (+0.5%)
|
313.26M
est: 350.00M (-10.5%)
|
264.03M
est: 200.00M (+32.0%)
|
202.19M
est: 184.00M (+9.9%)
|
135.51M
est: 1.20B (-88.7%)
|
108.52M
est: 108.52M (+0.0%)
|
| EBITDA |
-1.09B
est: -670.00M (-62.4%)
|
-2.05B
est: -204.00M (-906.4%)
|
-2.69B
est: -345.00M (-679.6%)
|
-5.32B
est: -216.67M (-2,357.1%)
|
-1.79B
est: -473.00M (-278.9%)
|
-1.10B
est: -550.00M (-100.6%)
|
-1.30B
est: -350.00M (-271.4%)
|
-2.06B
est: -200.00M (-928.3%)
|
-1.25B
est: -184.00M (-577.1%)
|
-863.31M
est: -1.20B (+28.1%)
|
-755.33M
est: -108.52M (-596.1%)
|
| EBIT |
-1.11B
est: -670.00M (-65.4%)
|
-2.08B
est: -204.00M (-920.9%)
|
-2.71B
est: -345.00M (-686.2%)
|
-5.35B
est: -216.67M (-2,369.9%)
|
-1.80B
est: -473.00M (-281.0%)
|
-1.11B
est: -550.00M (-101.1%)
|
-1.30B
est: -350.00M (-272.3%)
|
-2.06B
est: -200.00M (-930.5%)
|
-1.25B
est: -184.00M (-577.2%)
|
-864.42M
est: -1.20B (+28.0%)
|
-755.35M
est: -108.52M (-596.1%)
|
| Net Income |
-207.16M
est: -401.95M (+48.5%)
|
-2.54B
est: -4.35B (+41.7%)
|
-2.68B
est: -4.80B (+44.2%)
|
-5.42B
est: -8.66B (+37.4%)
|
-1.81B
est: -3.15B (+42.5%)
|
-2.01B
est: -2.50B (+19.7%)
|
-2.84B
est: -3.17B (+10.4%)
|
-1.88B
est: -1.81B (-3.8%)
|
-1.31B
est: -1.48B (+11.5%)
|
-780.00M
est: -1.71B (+54.5%)
|
-835.38M
|
| SGA |
463.84M
est: 1.83B (-74.6%)
|
391.23M
est: 555.92M (-29.6%)
|
527.15M
est: 940.16M (-43.9%)
|
464.43M
est: 590.44M (-21.3%)
|
362.20M
est: 1.29B (-71.9%)
|
310.64M
est: 1.50B (-79.3%)
|
320.80M
est: 953.79M (-66.4%)
|
287.94M
est: 545.02M (-47.2%)
|
284.70M
est: 501.42M (-43.2%)
|
327.97M
est: 2.34B (-86.0%)
|
411.03M
est: 211.19M (+94.6%)
|
| EPS |
-5.12
est: -5.70 (+10.2%)
|
-59.53
est: -61.75 (+3.6%)
|
-62.07
est: -68.00 (+8.7%)
|
-125.39
est: -122.80 (-2.1%)
|
-39.14
est: -44.60 (+12.2%)
|
-32.68
est: -35.50 (+7.9%)
|
-41.53
est: -44.90 (+7.5%)
|
-26.90
est: -25.70 (-4.7%)
|
-18.70
est: -21.00 (+11.0%)
|
-11.10
est: -24.30 (+54.3%)
|
-11.85
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-1.96M
OE per share TTM
-0.03
Owner's Yield
-0.02%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
0.7%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-536.7K
Shares Outstanding
73.96M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Atsushi Matsumura | Executive Chairperson of the Board | — | male |
| Koji Fujimoto | Executive Officer & Chief Financial Officer | — | male |
| Shiro Akinaga | President, Chief Executive Officer & Representative Director | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4571.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
